Evaxion Biotech A/S
EVAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $7,492 | $37 | $0 | $122 |
| % Growth | 20,148.6% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $7,492 | $37 | $0 | $122 |
| % Margin | 100% | 100% | – | 100% |
| R&D Expenses | $3,092 | $2,165 | $2,156 | $2,255 |
| G&A Expenses | $1,377 | $2,212 | $1,712 | $1,589 |
| SG&A Expenses | $1,377 | $2,212 | $1,712 | $1,589 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | $0 | $0 | $302 |
| Operating Expenses | $4,470 | $4,377 | $3,868 | $4,146 |
| Operating Income | $3,022 | -$4,340 | -$3,868 | -$4,024 |
| % Margin | 40.3% | -11,729.7% | – | -3,298.4% |
| Other Income/Exp. Net | $1,330 | -$686 | $2,096 | $120 |
| Pre-Tax Income | $4,352 | -$5,026 | -$1,772 | -$3,904 |
| Tax Expense | -$265 | -$195 | -$192 | -$275 |
| Net Income | $4,618 | -$4,831 | -$1,580 | -$3,629 |
| % Margin | 61.6% | -13,056.8% | – | -2,974.6% |
| EPS | 4.2 | -4.4 | -1.43 | -3.4 |
| % Growth | 195.5% | -207.7% | 57.9% | – |
| EPS Diluted | 4.2 | -4.4 | -0.5 | -3.4 |
| Weighted Avg Shares Out | 1,105 | 1,105 | 1,105 | 1,073 |
| Weighted Avg Shares Out Dil | 1,105 | 1,105 | 1,105 | 1,073 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,690 | $30 | $2,493 | $0 |
| Interest Expense | $1,360 | $241 | $397 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $91 |
| EBITDA | $5,712 | -$4,785 | -$1,375 | -$5,516 |
| % Margin | 76.2% | -12,932.4% | – | -4,521.5% |